Molecular Diagnostic Reimbursement Outlook

Paradigms for MolDX Coverage with Gabe Bien-Willner

In this webinar, Gabe Bien-Willner, Medical Director, MolDX discusses: – How to navigate policies of Medicare -How coverage is determined – Understanding the metrics Medicare uses to measure their tests

Presented by: Gabriel A. Bien-Willner, MD, PhD, FCAP Medical Director, MolDX Chief Medical Officer, Palmetto GBA

Hosted by: Matt Takahashi President, Executive BioSearch Executive and Scientific Search in Molecular Diagnostics

About the Presenter: Dr. Bien-Willner is the Medical Director of the MolDX program at Palmetto GBA, a Medicare Administrative Contractor (MAC).

MolDX seeks to understand the molecular testing landscape to implement payer controls, coverage, and to set policy for affiliated MACs, which currently cover 28 states.

He is a leader in the Precision Medicine space and practices as a Board-certified Anatomic Pathologist and Molecular Genetic Pathologist. Throughout his career, he has been active in research, development, and advancement of molecular diagnostic services, specifically next generation sequencing.

He has worked closely with clinicians to develop clear clinical diagnostic and treatment pathways directing Precision Medicine programs for community cancer centers.

Dr. Bien-Willner received his MD and PhD degrees from Baylor College of Medicine, with a PhD in Human Molecular Genetics. He completed his residency, fellowship, and attained a faculty appointment at Washington University in St. Louis prior to leadership roles in laboratory and biotech companies before joining Palmetto GBA.